A review of the government’s Strategy for UK Life Sciences has found that eight out of the 13 initiatives reviewed have made notable progress towards the actions and commitments set out in the original strategy, but there is still much more work to do to meet the strategy’s original objectives.
To see LifeSciencesUK's report - click here.
On Monday 3rd February, BIVDA responded to the NICE Consultation on the Quality Outcomes Framework (QOF) with reference to the Diabetes Indicator.
To see our response click here.
Following the submission of written evidence to the Science and Technology Committee's Inquiry into Anti Microbial Resistance (AMR), Doris-Ann was invited to give Oral Evidence.
As follows are the key health policy issues, as well as wider announcements, covered in the Autumn Statement made by the Chancellor of the Exchequer, George Osborne MP, to Parliament on Thursday 5 December.
£10 million competition for business to map rare cancer genes
Winning companies will be funded to develop high-tech products to help identify and treat inherited diseases and cancer. Ideas could include new computer code or hardware, or improvements of existing software and devices.
Health Minister Lord Howe has launched the first UK Rare Diseases Strategy. The strategy aims to help build understanding of rare diseases, and increase research to find effective treatments and therapies. The Government has also announced that the National Institute for Health Research (NIHR) will establish a Rare Diseases Translational Research Collaboration (TRC), which will be given £20 million over a period of four years.
BIVDA has responded to the Science and Technology Committee's inquiry into antimicrobial resistance, following the Department of Health's Five Year Antimicrobial Resistance Strategy, 2013-2018.
Click through to read the NIC Concordat and find more information on NIC Pilot 4
BIVDA is pleased to respond to the MHRA’s public consultation on the revision of European legislation Medical Devices and In Vitro Diagnostics
The British In Vitro Diagnostics Association (BIVDA) welcomes today’s announcement that there will be a review of quality assurance arrangements for NHS pathology services.
Policy & Media
BIVDA Press Releases
Click here to view more of our Parliamentary Newsletters
©2013 BIVDA BIVDA Ltd is registered in England, with Company Number 2687137
Registered Office is Devonshire House (2nd floor), 164-168 Westminster Bridge Road, London, SE1 7RW VAT Number 563105858